Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 70.1487
- Book/Share 37.7947
- PB 9.2013
- Debt/Equity 0.5906
- CurrentRatio 0.784
- ROIC 0.3934
- MktCap 1545295424973.4841
- FreeCF/Share 13.9401
- PFCF 24.9285
- PE 13.9232
- Debt/Assets 0.2059
- DivYield 0.031
- ROE 0.7786
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
| Downgrade | NVO | UBS | Buy | Neutral | -- | -- | Aug. 5, 2025 |
| Downgrade | NVO | HSBC Securities | Buy | Hold | -- | $57 | July 31, 2025 |
| Downgrade | NVO | Barclays | Overweight | Equal Weight | -- | -- | July 30, 2025 |
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
News
The Ozempic maker shakes up its board. It has been a year of turmoil for Novo Nordisk.
Published: October 21, 2025 by: Market Watch
Sentiment: Negative
Ozempic maker Novo Nordisk is shaking up its board.
Read More
Novo Nordisk in active talks with Trump administration on MFN
Published: October 21, 2025 by: CNBC Television
Sentiment: Positive
Novo Nordisk U.S. President Dave Moore confirms the company is in active discussions with the Trump administration over most favored nation pricing for its popular GLP-1 drugs Ozempic and Wegovy, as it wraps up talks for the IRA Medicare drug price negotiations. It comes as the company is ramping up its U.S. manufacturing capabilities ahead of the anticipated approval of Wegovy in pill form.
Read More
Novo Nordisk board members step down after clash with controlling shareholder
Published: October 21, 2025 by: CNBC
Sentiment: Negative
Novo Nordisk directors and the firm's controlling shareholder failed to reach an agreement on the future composition of the board.
Read More
Novo Nordisk Chair Helge Lund and six other board members to step down
Published: October 21, 2025 by: Reuters
Sentiment: Neutral
Wegovy-maker Novo Nordisk said on Tuesday its Chair Helge Lund and six other board members will step down at an upcoming extraordinary general meeting on November 14.
Read More
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Oct 2025)
Published: October 21, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Ozempic has become a phenomenon, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Read More
Insight: Novo Nordisk fights to keep Medicaid paying for weight-loss drugs
Published: October 21, 2025 by: Reuters
Sentiment: Neutral
Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as some U.S. states struggle with the treatment's costs, according to state documents, company emails and interviews with lawmakers and advocates.
Read More
My Top 3 Pharma Stocks
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Read More
2 Beaten-Down Stocks to Buy and Hold for the Next Decade
Published: October 20, 2025 by: The Motley Fool
Sentiment: Positive
The market is forward-looking, but investors who earn better-than-average returns often look even further into the future and identify opportunities that are currently being overlooked. That means, among other things, buying shares of companies that are lagging the market but can bounce back over the midterm and beyond.
Read More
NVO and LLY Stocks Slide as Trump Signals Price Cuts for GLP-1 Drugs
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Trump's pledge to slash GLP-1 drug prices sends Novo Nordisk and Eli Lilly shares tumbling, raising questions about the feasibility of such a development.
Read More
Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks
Published: October 17, 2025 by: Investopedia
Sentiment: Negative
Novo Nordisk (NVO) and Eli Lilly (LLY) shares slumped in early trading Friday after President Trump promised to lower the prices of popular weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Lilly's Zepbound.
Read More
Is Trump Going to Kill the GLP-1 Cash Cow?
Published: October 17, 2025 by: 24/7 Wall Street
Sentiment: Negative
GLP-1 drugs propelled Novo Nordisk (NVO) and Eli Lilly (LLY) to record profits, with sales exceeding $20 billion amid skyrocketing demand. Both companies cut prices recently to expand access, but President Trump's vow threatens deeper reductions.
Read More
Novo Nordisk, Eli Lilly shares drop as Trump promises lower weight loss drug prices
Published: October 17, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY), two major pharmaceutical companies that produce weight-loss drugs, dropped sharply following comments from US president Donald Trump about reductions in the prices of these medicines. During a White House event focused on fertility treatments and drug pricing, Trump suggested that the cost of drugs like Novo Nordisk's Ozempic (semaglutide), used for diabetes and weight management, would soon be “much lower.
Read More
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.
Read More
Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case
Published: October 16, 2025 by: Seeking Alpha
Sentiment: Positive
Omeros Corporation's stock surged over 150% after licensing zaltenibart to Novo Nordisk for $340M upfront, plus milestones and royalties. The deal provides OMER with critical funding, alleviating bankruptcy concerns and supporting operations through 2027 as it pursues FDA approval for narsoplimab. Zaltenibart's unique MASP-3 inhibition offers advantages in PNH, attracting NVO, which seeks to diversify beyond semaglutide amid recent headwinds.
Read More
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.
Read More
Novo Nordisk begins round of layoffs in United States, sources say
Published: October 15, 2025 by: Reuters
Sentiment: Negative
Drugmaker Novo Nordisk has begun a round of layoffs in its most important market, the United States, with affected staff set to be notified between this week and next, according to an email and two sources familiar with the matter.
Read More
Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug
Published: October 15, 2025 by: WSJ
Sentiment: Positive
Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart.
Read More
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Novo Nordisk halts work on cell therapy for diabetes to cut costs, Bloomberg News reports
Published: October 10, 2025 by: Reuters
Sentiment: Negative
Novo Nordisk has cut its cell therapy division, which has been trying to find a cure for type 1 diabetes, Bloomberg News reported on Friday, citing a statement.
Read More
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
Read More
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
Published: October 09, 2025 by: Zacks Investment Research
Sentiment: Negative
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.
Read More
Novo Nordisk A/S (NVO) M&A Call Transcript
Published: October 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Novo Nordisk A/S (NVO) M&A Call October 9, 2025 8:00 AM EDT Company Participants Jacob Martin Rode - Head of Investor Relations Maziar Doustdar - President, CEO & Member of the Management Board Ludovic Helfgott - Executive VP of Product & Portfolio Strategy and Member of Management Board Martin Lange - EVP of R&D, CSO and Member of the Management Board Conference Call Participants Harry Sephton - UBS Investment Bank, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Peter Verdult - BNP Paribas Exane, Research Division Conor MacKay - BMO Capital Markets Equity Research Michael Nedelcovych - …
Read More
Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug
Published: October 09, 2025 by: Fast Company
Sentiment: Positive
Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's new CEO to boost growth.
Read More
Akero Therapeutics Stock Surges on Novo Nordisk Buyout
Published: October 09, 2025 by: Schaeffers Research
Sentiment: Positive
Novo Nordisk A/S (NYSE:NVO) is down 1% to trade at $59 this morning, after news surfaced that the pharmaceutical concern has entered an agreement to purchase U.S.-based peer Akero Therapeutics Inc (NASDAQ:AKRO) for as much as $5.2 billion in cash.
Read More
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion
Published: October 09, 2025 by: Benzinga
Sentiment: Neutral
Novo Nordisk A/S (NYSE:NVO) agreed on Thursday to acquire Akero Therapeutics, Inc. (NASDAQ:AKRO) focused on metabolic diseases.
Read More
Novo Nordisk: CagriSema Sets Potential Obesity Drug Development Comeback
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
Downgrading Novo Nordisk from a "Strong Buy" rating to a "Buy" rating, whereby it may or may not be able to overcome competition in the obesity drug development space. Company faces competition from Eli Lilly's Zepbound, but ongoing REDEFINE and EVOKE studies could restore market share and expand indications. Key pipeline assets include CagriSema, Cagrilintide, and Amycretin, with multiple late-stage trials aiming for superior weight loss and safety.
Read More
"Exciting Race" Between LLY & NVO, Tariffs Remain Long-Term Overhang
Published: October 06, 2025 by: Schwab Network
Sentiment: Neutral
Lee Brown sees lots of potential in the weight loss drug space, noting Eli Lilly (LLY) and Novo Nordisk (NVO) as the two companies he expects to lead. He points to "incredible" discounts and expanded access to GLP-1s as indicators these companies will see wider moats for their products.
Read More
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Novo Nordisk Is Primed For A Post-Earnings Recovery (Earnings Preview)
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk's Q2 2025 results showed resilient revenue growth, but profit guidance was cut due to U.S. competition, compounded drugs, and currency headwinds. I see the upcoming Q3 earnings and Alzheimer's trial data as critical catalysts that could restore confidence and drive a sustained stock recovery. The current valuation appears disconnected from NVO's growth prospects, supporting a 12-month price target of $65 and a longer-term target of $80.4.
Read More
Can NVO Maintain Obesity Leadership With Next-Generation Candidates?
Published: September 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Lars Fruergaard Jorgensen
- Employees 77406